The coronavirus pandemic led to blood-donation shortages across the world, outlining the fragility of the pipeline. That has brought fresh urgency to research that has been decades in the making but is only now starting to become a reality: The production of artificial blood. Last year, researchers began a pioneering clinical trial, and more are on the way, bringing us closer to a world where blood factories augment supplies.

Podden och tillhörande omslagsbild på den här sidan tillhör The Wall Street Journal. Innehållet i podden är skapat av The Wall Street Journal och inte av, eller tillsammans med, Poddtoppen.